Federal Register Notice: FDA’s Office of Orphan Product Development (OPD) is providing notice of a funding opportunity announcement for federal assistance. The goal of the OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. To view this notice, click here.